P 276

Drug Profile

P 276

Alternative Names: P-276-00; P276; Riviciclib

Latest Information Update: 11 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Piramal Life Sciences
  • Developer Piramal Enterprises; Piramal Healthcare
  • Class Antineoplastics; Chromans; Pyrrolidines
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Head and neck cancer; Malignant melanoma; Mucositis; Multiple myeloma; Pancreatic cancer
  • Discontinued Mantle-cell lymphoma; Solid tumours

Most Recent Events

  • 01 Sep 2014 Piramal terminates phase I/II trial in Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)
  • 01 Sep 2014 Piramal completes a phase I/II trial in the prevention of Radiation-induced mucositis in patients with locally advanced head and neck cancer receiving chemotherapy in India (NCT01903018)
  • 18 Jul 2013 Piramal completes enrolment in its phase II trial for Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top